Filtered By:
Condition: Cholestasis

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 50 results found since Jan 2013.

Yangonin protects against estrogen-induced cholestasis in a farnesoid X receptor-dependent manner.
In conclusion, yangonin alleviates estrogen-induced cholestasis, due to FXR-mediated gene regulation. PMID: 31220436 [PubMed - as supplied by publisher]
Source: European Journal of Pharmacology - June 16, 2019 Category: Drugs & Pharmacology Authors: Dong R, Wang J, Gao X, Wang C, Liu K, Wu J, Liu Z, Sun H, Ma X, Meng Q Tags: Eur J Pharmacol Source Type: research

Emodin Rescues Intrahepatic Cholestasis via Stimulating FXR/BSEP Pathway in Promoting the Canalicular Export of Accumulated Bile
Conclusions: Emodin has a protective effect and a rescue activity on cholestasis via stimulating FXR/BSEP pathways in promoting the canalicular export of accumulated bile.
Source: Frontiers in Pharmacology - May 21, 2019 Category: Drugs & Pharmacology Source Type: research

Taurocholate Induces Connective Tissue Growth Factor Expression in Hepatocytes Through ERK-YAP Signaling
Conclusion: Our report provides evidence for the role of conjugated BAs in liver fibrosis and suggests that the production of CTGF/CCN2, induced by conjugated BAs via ERK-YAP axis activation, may be a therapeutic target in cholestasis-induced liver fibrosis.Cell Physiol Biochem 2018;50:1711 –1725
Source: Cellular Physiology and Biochemistry - November 1, 2018 Category: Cytology Source Type: research

Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
Abstract Cholestasis is a clinical syndrome with systemic and intrahepatic accumulation of excessive toxic bile acids that ultimately cause hepatobiliary injury. Recently obeticholic acid (OCA) which is a farnesoid X receptor (FXR) agonist was approved by FDA to treat cholestatic liver diseases, which provided us a newly therapeutic strategy against cholestasis. The purpose of the current study is to screen novel FXR agonists and verify the anti-cholestasis effect of yangonin in vivo and in vitro. The computational strategy of two-dimensional virtual screening was used to search for new FXR agonists, and dual-luci...
Source: Toxicology and Applied Pharmacology - April 13, 2018 Category: Toxicology Authors: Gao X, Fu T, Wang C, Ning C, Liu K, Liu Z, Sun H, Ma X, Huo X, Yang X, Zou M, Meng Q Tags: Toxicol Appl Pharmacol Source Type: research

Mechanisms of canalicular transporter endocytosis in the cholestatic rat liver
In conclusion, our findings show that CME is the mechanism responsible for the internalization of the canalicular transporters BSEP and MRP2 in E17G-induced cholestasis. The shift of these transporters from raft to non-raft microdomains could be a prerequisite for the transporters to be endocytosed under cholestatic conditions.
Source: Biochimica et Biophysica Acta (BBA) Molecular Basis of Disease - March 1, 2018 Category: Molecular Biology Source Type: research

Effects of corilagin on alleviating cholestasis via farnesoid X receptor ‐associated pathways in vitro and in vivo
Conclusions and ImplicationsCorilagin exerts a protective effect in hepatocytes and can prevent the deleterious activities of intrahepatic cholestasis by stimulating FXR‐associated pathways.
Source: British Journal of Pharmacology - January 25, 2018 Category: Drugs & Pharmacology Authors: Fan Yang, Yao Wang, Gang Li, Juan Xue, Zhi ‐Lin Chen, Feng Jin, Lei Luo, Xuan Zhou, Qian Ma, Xin Cai, Hua‐Rong Li, Lei Zhao Tags: RESEARCH PAPER Source Type: research

Bile acids stimulate cholangiocyte fluid secretion by activation of membraneTMEM16A Cl ‐ channels
Conclusion: Bile acids stimulate Cl‐ secretion in mouse and human biliary cells through activation of membrane TMEM16A channels in a process regulated by extracellular ATP and [Ca2+]i. These studies suggest that TMEM16A channels may be targets to increase bile flow during cholestasis. This article is protected by copyright. All rights reserved.
Source: Hepatology - January 23, 2018 Category: Internal Medicine Authors: Qin Li, Amal Dutta, Charles Kresge, Abhijit Bugde, Andrew P. Feranchak Tags: Autoimmune, Cholestatic and Biliary Disease Source Type: research

Mechanisms of canalicular transporter endocytosis in the cholestatic rat liver.
In conclusion, our findings show that CME is the mechanism responsible for the internalization of the canalicular transporters BSEP and MRP2 in E17G-induced cholestasis. The shift of these transporters from raft to non-raft microdomains could be a prerequisite for the transporters to be endocytosed under cholestatic conditions. PMID: 29355600 [PubMed - as supplied by publisher]
Source: Biochimica et Biophysica Acta - January 17, 2018 Category: Biochemistry Authors: Miszczuk GS, Barosso IR, Larocca MC, Marrone J, Marinelli RA, Boaglio AC, Sánchez Pozzi EJ, Roma MG, Crocenzi FA Tags: Biochim Biophys Acta Source Type: research

Effects of corilagin on alleviating cholestasis via FXR ‐associated pathways in vitro and in vivo
CONCLUSIONS AND IMPLICATIONSCorilagin exerts a protective effect in hepatocytes and can rescue the deleterious activities of intrahepatic cholestasis by stimulating FXR‐associated pathways.
Source: British Journal of Pharmacology - December 1, 2017 Category: Drugs & Pharmacology Authors: Fan Yang, Yao Wang, Gang Li, Juan Xue, Zhi ‐Lin Chen, Feng Jin, Lei Luo, Xuan Zhou, Qian Ma, Xin Cai, Hua‐Rong Li, Lei Zhao Tags: RESEARCH PAPER Source Type: research

Activation of insulin-like growth factor 1 receptor participates downstream of GPR30 in estradiol-17 β-D-glucuronide-induced cholestasis in rats.
In conclusion, the activation of IGF-1R is a key factor in the alteration of canalicular transporter function and localization induced by E17G, and its activation follows that of GPR30 and precedes that of PI3K/Akt. PMID: 29090346 [PubMed - as supplied by publisher]
Source: Archives of Toxicology - October 31, 2017 Category: Toxicology Authors: Barosso IR, Miszczuk GS, Ciriaci N, Andermatten RB, Maidagan PM, Razori V, Taborda DR, Roma MG, Crocenzi FA, Sánchez Pozzi EJ Tags: Arch Toxicol Source Type: research

Computational discovery and experimental verification of farnesoid X receptor agonist auraptene to protect against cholestatic liver injury.
Abstract Recently obeticholic acid (OCA) which is a farnesoid X receptor (FXR) agonist was approved by FDA to treat cholestatic liver diseases, which provided us a novel therapeutic strategy against cholestasis. Herein, we used a novel computational strategy with two-dimensional virtual screening for FXR agonists. For the first time, we found that auraptene (AUR), a natural product, can activate FXR to exert hepatoprotective effect against cholestatic liver injury in vivo and in vitro. Importantly, AUR was found to significantly decrease the mortality of cholestatic mice. Dynamic change analysis of bile acids and ...
Source: Biochemical Pharmacology - October 4, 2017 Category: Drugs & Pharmacology Authors: Gao X, Fu T, Wang C, Ning C, Kong Y, Liu Z, Sun H, Ma X, Liu K, Meng Q Tags: Biochem Pharmacol Source Type: research

Increased hepatic ABCA1 transporter is associated with hypercholesterolemia in a cholestatic rat model and primary biliary cholangitis patients
This study aimed to determine the expression of hepatic ABCA1 levels in a cholestatic rat model and patients with primary biliary cholangitis (PBC). A cholesterol efflux study was conducted withAbca1 knock down using siRNA in WIF9 cells. Cholesterol levels in the ABCA1 siRNA cells in the medium were significantly decreased compared with those in controls (P <  0.05). Hepatic ABCA1 mRNA levels were significantly higher in BDL rats than in control rats (P <  0.05). Furthermore, the protein expression level of hepatic ABCA1 was also significantly increased by 200% in BDL rats (P <  0.05). In PBC patients, expre...
Source: Medical Molecular Morphology - June 28, 2017 Category: Molecular Biology Source Type: research

Calcineurin Inhibitors Downregulate HNF-1β and May Affect the Outcome of HNF1B Patients After Renal Transplantation
Conclusions: Because HNF1B-related disease is a heterozygous condition, CNIs used to prevent rejection may induce reduced expression of the nonmutated allele of HNF1B leading to a superimposed defect of HNF-1β transcriptional activity. Taking into account the specific risk of posttransplantation diabetes mellitus and liver disorders in HNF1B patients, these findings advocate for in-depth characterization of pathways that regulate HNF1B and plead for considering individually tailored graft management that may include a CNI-free immunosuppressive regimen. Interventional studies will have to confirm this individualized approach.
Source: Transplantation - August 24, 2016 Category: Transplant Surgery Tags: Original Clinical Science-General Source Type: research

Hsp90 and hepatobiliary transformation during sea lamprey metamorphosis
Conclusions: HSP90 appears to play crucial roles in hepatobiliary transformation during sea lamprey metamorphosis. Sea lamprey is a useful animal model to study postembryonic development and mechanisms for hsp90-induced hepatobiliary transformation.
Source: BMC Developmental Biology - December 1, 2015 Category: Zoology Authors: Yu-Wen Chung-DavidsonChu-Yin YehUgo BussyKe LiPeter DavidsonKaben NanlohyC. BrownSteven WhyardWeiming Li Source Type: research

EGFR participates downstream of ERα in estradiol-17β-D-glucuronide-induced impairment of Abcc2 function in isolated rat hepatocyte couplets.
In conclusion, activation of EGFR is a key factor in the alteration of canalicular transporter function and localization induced by E17G and it occurs before that of Src and after that of ERα. PMID: 25813982 [PubMed - as supplied by publisher]
Source: Archives of Toxicology - March 27, 2015 Category: Toxicology Authors: Barosso IR, Zucchetti AE, Miszczuk GS, Boaglio AC, Taborda DR, Roma MG, Crocenzi FA, Sánchez Pozzi EJ Tags: Arch Toxicol Source Type: research